STOCK TITAN

PureTech to Present at Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, has announced its management team's participation in two upcoming investor conferences. Bharatt Chowrira, CEO, and Eric Elenko, Co-founder and President, will present at the UBS Global Healthcare Conference on November 13, 2024, at 8:45 a.m. PST, and the Jefferies London Healthcare Conference on November 19, 2024, at 2:30 p.m. GMT. Webcasts of both presentations will be accessible through PureTech's investor relations website.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), una società di biotecnologia in fase clinica, ha annunciato la partecipazione del suo team di gestione a due prossime conferenze per investitori. Bharatt Chowrira, CEO, e Eric Elenko, cofondatore e presidente, presenteranno alla Conferenza Sanitaria Globale UBS il 13 novembre 2024, alle 8:45 PST, e alla Conferenza Sanitaria di Londra Jefferies il 19 novembre 2024, alle 14:30 GMT. I webcast di entrambe le presentazioni saranno accessibili attraverso il sito web delle relazioni con gli investitori di PureTech.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), una empresa de bioterapéuticos en fase clínica, ha anunciado la participación de su equipo de gestión en dos próximas conferencias para inversores. Bharatt Chowrira, CEO, y Eric Elenko, cofundador y presidente, presentarán en la Conferencia Global de Salud de UBS el 13 de noviembre de 2024, a las 8:45 a.m. PST, y en la Conferencia de Salud de Londres de Jefferies el 19 de noviembre de 2024, a las 2:30 p.m. GMT. Las retransmisiones de ambas presentaciones estarán disponibles a través del sitio web de relaciones con inversores de PureTech.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), 임상 단계의 생물 치료제 회사,가 두 개의 투자자 컨퍼런스에 경영진 팀의 참여를 발표했습니다. Bharatt Chowrira, CEO, 및 Eric Elenko, 공동 창립자 및 사장,은 2024년 11월 13일 오전 8시 45분 PST에 UBS 글로벌 헬스케어 컨퍼런스에서 발표하고, 2024년 11월 19일 오후 2시 30분 GMT에 Jefferies 런던 헬스케어 컨퍼런스에서 발표할 예정입니다. 두 발표의 웹 캐스트는 PureTech의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), une entreprise de biothérapeutiques en phase clinique, a annoncé la participation de son équipe de direction à deux conférences d'investisseurs à venir. Bharatt Chowrira, PDG, et Eric Elenko, cofondateur et président, présenteront à la Conférence Mondiale sur la Santé UBS le 13 novembre 2024 à 8h45 PST, et à la Conférence sur la Santé de Londres de Jefferies le 19 novembre 2024 à 14h30 GMT. Les webdiffusions des deux présentations seront accessibles sur le site de relations investisseurs de PureTech.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), ein biotherapeutisches Unternehmen in klinischen Phasen, hat die Teilnahme seines Management-Teams an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Bharatt Chowrira, CEO, und Eric Elenko, Mitgründer und Präsident, werden am 13. November 2024 um 8:45 Uhr PST auf der UBS Global Healthcare Conference und am 19. November 2024 um 14:30 Uhr GMT auf der Jefferies London Healthcare Conference präsentieren. Die Webcasts beider Präsentationen werden über die Investor-Relations-Website von PureTech zugänglich sein.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in two upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com.

UBS Global Healthcare Conference
Presenters: Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President
Date: Wednesday, November 13, 2024
Time: 8:45 a.m. PST

Jefferies London Healthcare Conference
Presenters: Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President
Date: Tuesday, November 19, 2024
Time: 2:30 p.m. GMT

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com

Source: PureTech Health

FAQ

When is PureTech (PRTC) presenting at the UBS Global Healthcare Conference 2024?

PureTech will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 8:45 a.m. PST.

What time is PureTech's (PRTC) presentation at the Jefferies London Healthcare Conference 2024?

PureTech will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 2:30 p.m. GMT.

Where can I watch PureTech's (PRTC) investor conference presentations?

Webcasts of PureTech's presentations will be available at https://investors.puretechhealth.com.

Who will represent PureTech (PRTC) at the 2024 investor conferences?

Bharatt Chowrira, CEO, and Eric Elenko, Co-founder and President, will represent PureTech at both conferences.

PureTech Health plc American Depositary Shares

NASDAQ:PRTC

PRTC Rankings

PRTC Latest News

PRTC Stock Data

519.42M
23.94M
0.13%
0.03%
Biotechnology
Healthcare
Link
United States of America
Boston